NCT05802225View on ClinicalTrials.gov

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

June 6, 2025

Study Completion Date

February 20, 2026

Conditions
Breast Cancer
Interventions
DRUG

BCD-178

at an initial dose of 840 mg (1 cycle), then 420 mg

DRUG

Perjeta

at an initial dose of 840 mg (1 cycle), then 420 mg

Trial Locations (3)

111123

The Loginov Moscow Clinical Scientific Center MHD, Moscow

190013

"JSC Modern Medical Technologies", Saint Petersburg

Unknown

"Budgetary healthcare institution of the Omsk region Clinical oncological dispensary", Omsk

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT05802225 - Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer | Biotech Hunter | Biotech Hunter